Avigen is a Contract Research Organisation specializing in avidity-based assays for immunotherapy and cell therapy R&D. The platform measures single-cell immune-target interactions with high throughput to identify and rank potent therapeutic candidates. This service accelerates the discovery and validation process for cellular immunotherapies across various indications.
Funding
Funding not disclosed
Founders
Product
Problem
Identifying and validating potent immune cells for cellular immunotherapies is a complex process that requires precise measurement of cellular avidity. Traditional methods often lack the throughput and physiological relevance needed to accurately assess these interactions, hindering the development of effective treatments for solid tumors.
Solution
Avigen operates as a contract research organization (CRO) specializing in accelerating immunotherapy development. Our proprietary platform integrates microfluidics with advanced biological insights to measure cellular avidity, enabling the identification and validation of high-efficacy immune cells. This approach provides physiologically relevant, high-throughput, and gentle single-cell interaction analysis, crucial for advancing cellular immunotherapies targeting solid tumor indications. We offer a comprehensive solution to streamline the discovery and validation pipeline for novel cell-based therapeutics.
Target Audience
Our primary clients are biotechnology and pharmaceutical companies focused on developing cellular immunotherapies for solid tumor indications.
Features
- Microfluidic platform for high-throughput single-cell interaction analysis
- Cellular avidity measurement to quantify immune cell potency
- Physiological relevance by capturing live immune-target cell interactions
- Maintains cell viability for downstream functional assays
- Adaptable to various immune cell types (TCR-T, CAR-T, NK) and adherent target cells
- Supports analysis across diverse solid tumor indications
- Enables comprehensive profiling of immune cell populations